Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV003456980 | SCV004184685 | uncertain significance | not provided | 2023-11-01 | criteria provided, single submitter | clinical testing | MAPT: PM2:Supporting, PS4:Supporting, BP4 |
Labcorp Genetics |
RCV003514643 | SCV004298245 | uncertain significance | Frontotemporal dementia | 2023-08-28 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Experimental studies have shown that this missense change affects MAPT function (PMID: 24121548, 27641626). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt MAPT protein function. This missense change has been observed in individuals with clinical features of frontotemporal dementia (PMID: 24121548, 29253099). This variant is present in population databases (rs777148159, gnomAD 0.003%). This sequence change replaces asparagine, which is neutral and polar, with histidine, which is basic and polar, at codon 410 of the MAPT protein (p.Asn410His). |